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ABSTRACT
Introduction: A single dose or short course of
primaquine given to people infected with malaria may
reduce transmission of Plasmodium falciparum
through its effects on gametocytes. Primaquine is also
known to cause haemolysis in people with variants of
glucose-6-phosphate dehydrogenase (G6PD)
deficiency. The objective of this systematic review was
to assess the risk of adverse effects in people with
G6PD deficiency given primaquine or other 8-
aminoquinoline (8AQ) as a single dose or short course
(less than 7 days).
Methods and analysis: We will search the following
databases: Cochrane Infectious Diseases Group
Specialized Register, the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE and
LILACS. Prospective cohort studies, randomised and
quasi-randomised trials that evaluated 8AQs for
whatever reason in adults or children with a known
G6PD deficiency will be included. Two authors will
independently assess each study for eligibility, risk of
bias and extract data.
Ethics and dissemination: This systematic review
will be published in a peer-reviewed journal. Brief
reports of the review findings will be disseminated
directly to the appropriate audiences and the WHO
Technical Expert Group in Malaria Chemotherapy. As
no primary data collection will be undertaken, no
additional formal ethical assessment and informed
consent are required.
Protocol registration in PROSPERO: The protocol
is registered with PROSPERO, registration number
CRD42013006518.
INTRODUCTION
Primaquine (PQ) has been the most com-
monly used 8-aminoquinoline (8AQ) anti-
malarial drug. Over the last 60 years, PQ has
been used to treat the liver stages (hypno-
zoites) of Plasmodium vivax and Plasmodium
ovale malaria to prevent relapses, and as a
single-dose or short-course gametocytocidal
drug with the goal of reducing transmission
of falciparum malaria.1 However, PQ still
carries a reputation of being an ‘unsafe’
drug,2 with side effects falling into three
main categories2 3
▸ the drug can cause a dose-dependent
acute haemolytic anaemia in individuals
who have glucose-6-phosphate dehydro-
genase (G6PD) deficiency2 4–6
▸ it can result in an increased level of meth-
aemoglobin, which is usually mild and
well tolerated7
▸ PQ can cause abdominal pain when taken
on an empty stomach.1 8
G6PD deficiency is a complicated disorder
(see box 1). It is common with an estimated
400 million people worldwide carrying a
mutation in the G6PD gene9–11 and also
widespread in malaria endemic countries
where PQ is potentially useful for malaria
control and elimination.11 The estimated
proportion of individuals carrying a G6PD
deficiency gene varies from 5% to as much
as 33% in different parts of sub-Saharan
Africa and Asia.6 11 Malaria and G6PD defi-
ciency share the same geographical distribu-
tion9 11 and some authorities think that
G6PD deficiency may be protective against
malaria.9 11–14
Strengths and limitations of this study
▪ The research team will provide an independent
analysis, based on long experience in research
synthesis.
▪ The team will evaluate the risk of bias in relation
to the primary studies, and interpret the findings
of the review in the light of these assessments.
▪ The quality of the adverse effects data in the
studies may be low and prone to high risk of
bias, since the reporting and description of
adverse events are generally poor.
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Epidemiology
G6PD deficiency has X-linked inheritance, making the
deficiency more variable in women.11 15–18 Women can
be homozygous for G6PD deficiency (when a woman
inherits the two deficient alleles of the G6PD gene one
from eachparent) or heterozygous (when a woman
inherits one normal and one abnormal gene). Men can
only be normal or hemizygous for G6PD deficiency
(because men have only one copy of the G6PD
gene).11 15–18 Heterozygous women have two popula-
tions of erythrocytes, one G6PD deficient and the other
with normal G6PD function.11 15–18 However, the ratio
of normal to deficient cells can vary due to the phenom-
enon of lyonisation.19 Lyonisation is a random process
and the resulting proportions of normal and deficient
cells may deviate significantly from the expected 50:50
ratio,15 19 leading some heterozygotes to have virtually
normal expression, and others with expression levels
comparable with female homozygotes (ie, entirely defi-
cient). At the population level, G6PD deficiency is more
commonly expressed in men, though in populations
with high frequencies of deficiency, homozygous inherit-
ance can be common, and the prevalence of affected
heterozygotes may be of public health concern.11
Haemolysis
Most individuals with G6PD deficiency have no clinical
manifestations and remain asymptomatic until they are
exposed to a haemolytic trigger, such as fava bean, PQ or
a severe infection.11 G6PD deficiency-induced haemolysis
is usually characterised clinically by fatigue, back pain,
anaemia and jaundice.9 20 It can also lead to a severe clin-
ical syndrome called blackwater fever, which is haemo-
globinuria coupled with acute renal failure.21 Although
the biomedical pathway leading to PQ-induced haemoly-
sis remains unclear, the severity of the clinical symptoms
depends on the degree of enzyme deficiency (which is
variant dependent), the total dose, the time course of
exposure and pre-existing factors like concurrent infec-
tion, age and haemoglobin (Hb) concentration.9 22
Transmission
PQ kills Plasmodium falciparum gametocytes and appears
to reduce or prevent infectiousness to mosquitoes in
laboratory experiments, although direct comparative evi-
dence for this effect is limited.23 24 The WHO has
recommended PQ for many years as a gametocytocidal
drug, with the intention of reducing P. falciparum trans-
mission in a community, although how widely it is actu-
ally used is not clear. The drug is usually given as a
single dose. In some of the older studies, the drug was
used in mass treatment campaigns alone25 or together
with a schizonticide,26 and increasingly the partner drug
for the asexual stages is an artemisinin-based combin-
ation therapy (ACT), which itself has effects on some
gametocytes.27 28 The potential reduction in transmis-
sion is important, but the drug does not benefit the indi-
vidual directly.
In 2010, the WHO1 malaria treatment guidelines
made a new recommendation (box 2, additional recom-
mendations in the second edition of the guidelines) for
PQ. The guidelines recommend the addition of a single
dose of PQ (0.75 mg/kg) to ACT for uncomplicated fal-
ciparum malaria as an antigametocyte medicine,
Box 1 G6PD classification
There are many variants of glucose-6-phosphate dehydrogenase
(G6PD) deficiency.9 11 One classification of G6PD deficiency is
based on enzyme activities and clinical manifestations39:
▸ Class I—severely deficient, associated with congenital non-
spherocytic haemolytic anaemia;
▸ Class II—severely deficient (1–10% residual activity), asso-
ciated with acute haemolytic anaemia;
▸ Class III—moderately deficient (10–60% residual activity);
▸ Class IV—normal activity (60–150%);
▸ Class V—increased activity (>150%).
Some important G6PD variants, with information about haem-
olysis, are:
▸ G6PD A—variant has 10–20% of the enzyme activity (Class II)
and is prevalent in Africa but also occurs in other popula-
tions.11 Primaquine sensitivity studies on ‘mild’ cases of
A-variant individuals of African origin found that
primaquine-induced haemolysis is usually self-limiting and
ends a few days after stopping treatment.11 40–42 The current
WHO recommendations for adults with ‘mild’ G6PD deficiency
are for 8 weekly 45 mg doses of primaquine.1 29 42 In addition
to preventing the severity of haemolysis, another important
benefit of extending the dosing schedule is the chance for
affected individuals with G6PD deficiency to have the oppor-
tunity to discontinue the primaquine before the severity of
haemolysis becomes too serious.11
▸ Mahidol variant is important in Myanmar and Thailand and
results in 5–32% normal level enzyme activity.43 One small
study that investigated the effects of primaquine for
Plasmodiumvivax in individuals with G6PD deficiency (n=22)
in Thailand who were given 15 mg primaquine for 14 days
with standard chloroquine treatment.44 No serious adverse
effects were reported and no patient required transfusion.
Buchachart and colleagues concluded that standard prima-
quine therapy would be safe in Thailand, even for those who
are G6PD deficient.44 However, although WHO recommended
that primaquine should be used for P. vivax radical cure in
this region, they also recommended prior G6PD testing.1
Recht cautioned that the evidence base for these recommen-
dations is relatively scanty and inconclusive.11 31 Mahidol var-
iants are heterogeneous, and even if a handful of studies have
reported no serious adverse reactions to primaquine, these
studies may not have included patients with severe G6PD
variants.11
▸ Mediterranean variant is widely seen in the Mediterranean
region and Middle East. It reduces enzyme activity to 1–10%
(Class II) of normal levels, thereby causing one of the most
severe forms of G6PD deficiency. In addition,
primaquine-induced haemolysis in the Mediterranean variant
is not self-limiting like A-variant.11 45 WHO guidelines state
that primaquine should not be given to individuals with such a
severe deficiency.1 29
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particularly as a component of a pre-elimination or an
elimination programme. No evidence was provided to
underpin this recommendation, although annex 4 to
the guidelines contains expert opinion on the topic. In
2010, 20 countries outside of Africa had already
included this recommendation for single-dose PQ in
their national treatment guidelines for uncomplicated
P. falciparum,29 although a dose of 0.5 mg/kg was some-
times recommended rather than 0.75 mg/kg.
Recent developments
The emergence of artemisinin resistance in P. falciparum
in the Mekong area has had led to interest in PQ’s
potential value, potentially at lower doses, for interrupt-
ing P. falciparum transmission28 30 to prevent the trans-
mission of drug resistant strains. The threat of adverse
events, however, remains in the background. A recent
narrative summary of the literature on 8AQs31 high-
lighted the adverse effects seen in higher doses, and
also noted that in the past it had been used routinely in
large malaria control programmes without apparent pro-
blems, for example, the use of quinocide and plasmo-
cide in Russia.32 Drawing on the published review, a
WHO policy update was issued in October 201233
recommending that:
In: (1) areas threatened by artemisinin resistance where
single dose primaquine as a gametocytocide for
P. falciparum malaria is not being implemented, and
(2) elimination areas which have not yet adopted prima-
quine as a gametocytocide for P. falciparum malaria:
A single 0.25 mg/base/kg primaquine dose should be
given to all patients with parasitologically confirmed
P. falciparum malaria on the first day of treatment in
addition to an ACT, except for pregnant women and
infants <1 year of age.
This new guideline was based on the results of the
safety literature review,31 the report of the evidence
review group,6 and other publications suggesting that
the lower dose of 0.25 mg/kg would (1) still be effective
at blocking transmission, and (2) have no adverse
effects, even in those who are G6PD deficient.28 30 34
Independent assessments
PQ at >0.5 mg/kg (and probably lower doses) acts on
gametocytes and reduces transmission of malaria from
mosquitoes in individual patients. The overall predicted
infectiousness, estimated by the area under the curve of
gametocyte prevalence and density, is reduced by about
half after a single dose.24 There remains a debate about
whether this will result in meaningful reduction in trans-
mission on a population basis, where there may be large
numbers of asymptomatic or untreated infectious
persons, poor timing of PQ treatment compared to
timing of gametocyte presence or short-drug half life.
The evidence on safety is less clear. The WHO guide-
line33 was based on an evidence review group report6
that summarised existing published literature, but it did
not use standard synthesis approaches to critically
appraise the evidence.
While the summary is a comprehensive collection of
the current literature, there is a need to appraise this in
the light of the quality of the data collected.34
Rationale for this review
The unpublished review by Recht et al35 compiled pub-
lished and unpublished studies on the safety of 8AQs.
This review is comprehensive but did not attempt to
examine the accuracy or quality of the primary studies
measuring risk. The existing Cochrane review of effective-
ness of PQ for reducing transmission is currently being
updated and expanded to include 8AQs other than PQ.
There is a need for a systematic review to evaluate the
safety of PQ and other 8AQs when used at low doses
(0.25 mg/kg) in persons with G6PD deficiency so that
guidelines can be based on the best possible evidence.
Aim
To assess the risk of haemolysis in people with G6PD
deficiency given PQ or other 8AQ as a single dose or
short course (less than 7 days).
OBJECTIVES
1. To assess the incidence of haemolysis (measured
using Hb/red blood cell/haematocrit (HCT)/
packed cell volume (PCV)) in:
A. patients with G6PD deficiency who receive short
course (<7 days) PQ (or other 8AQ) in comparison
with those who receive placebo/no intervention;
Box 2 MEDLINE search strategy
1. antimalarials
2. 8-aminoquinolone
3. primaquine
4. 1 OR 2 OR 3
5. g-6-pd
6. glucose 6 phosphate dehydrogenase
7. g6pd deficiency
8. glucosephosphate dehydrogenase deficiency
9. 5 OR 6 OR 7 OR 8
10. 4 AND 9
11. haemoly*
12. hemoly*
13. 11 OR 12
14. primaquine-sensitiv*
15. 13 OR 14
16. Primaquine*
17. sensitive*
18. 16 AND 17
19. 15 OR 18
20. 19 AND 4
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B. patients given short course (<7 days) PQ (or
other 8AQ) with G6PD deficiency, in comparison
with those without G6PD deficiency.
2. To explore the effect of G6PD phenotypic variations
and PQ dose on the incidence of haemolysis.
METHODS AND ANALYSIS
The protocol is registered with PROSPERO, registration
number CRD42013006518.36
Criteria for considering studies for this review
Types of studies
Randomised, quasi-randomised trials and prospective
cohort studies (containing non-randomised comparisons
or uncontrolled single-arm cohorts).
Retrospective case series (where patients with haem-
olysis are identified, and then retrospectively examined
for G6PD deficiency and PQ use) will be excluded. We
will exclude in vitro studies.
Types of participants
Adults or children who have been tested for G6PD defi-
ciency, using percentage enzyme activity, genotype, rapid
fluorescent spot test or any other method as reported by
the authors of the primary study.
We will not include studies that exclude patients with
G6PD deficiency.
Types of interventions
Single dose or short course (up to 7 days) of 8AQ.
Types of outcome measures
Main outcomes
▸ Measure of change of Hb, HCT or PCV.
▸ Measures of change in Hb plus additional evidence
of haemolysis, such as clinical (haematuria, jaundice)
or laboratory (bilirubin, red cell morphology)
measures.
Other outcomes
▸ Patients requiring a blood transfusion
▸ Patients requiring dialysis
▸ All-cause mortality.
Search methods for identification of studies
We will identify all relevant trials, regardless of language
or publication status (published, unpublished, in press
and in progress).
Electronic searches
The following databases will be searched: Cochrane
Infectious Diseases Group Specialized Register, the
Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Scopus, Web of Science;
EMBASE and LILACS (see box 2 for full MEDLINE
search strategy).
Conference proceedings
We will search the following conference proceedings for
relevant abstracts: the MIM Pan-African Malaria
Conferences and the American Society of Tropical
Medicine and Hygiene (ASTMH).
Searching other resources
We will contact researchers and other experts in the
field of malaria chemotherapy, including those at WHO.
We will check the reference lists of all studies identified
by the above methods.
Data collection and analysis
Selection of studies
Two authors will evaluate the eligibility of studies using a
pretested form, working independently to scan all
abstracts and obtain full text of articles. In cases of dis-
crepancy, agreement will be reached by discussion. If
further clarification is necessary we will attempt to
contact the authors for more information.
Data extraction and management
Two authors will independently extract data using a data
extraction form. We will extract data on study character-
istics including:
▸ Study design: Methods, site, year, outcomes.
▸ Participants: Age, sex, baseline parasitaemia, baseline
Hb.
▸ Intervention: Drug dose and regimen, co-interventions.
▸ Safety monitoring: G6PD test used, frequency of safety
monitoring, length of follow-up.
We will calculate and report the loss to follow-up in
each group by extracting the number of individuals par-
ticipating and the number analysed in each treatment
group for each outcome.
For dichotomous outcomes, we will record the
number of participants experiencing the outcome and
the number of participants in each treatment group. For
continuous outcomes, we will extract the arithmetic
means and SDs for each treatment group together with
the numbers of participants in each group. If the data
have been reported using geometric means, we will
record this information and extract SDs on the log scale.
If medians have been used we will also extract ranges.
Assessment of risk of bias
Two authors will independently asses the methodological
quality of all studies and discuss any differences of
opinion. We will use the EPOC criteria37 to assess for bias:
▸ Was the allocation sequence adequately generated?
▸ Was the allocation adequately concealed?
▸ Were baseline outcome measurements similar?
▸ Were baseline characteristics similar?
▸ Were incomplete outcome data adequately addressed?
▸ Was knowledge of the allocated interventions
adequately prevented during the study?
▸ Was the study free from selective outcome reporting?
▸ Was the study free from other risks of bias?
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We will categorise these judgements as ‘low’ risk of
bias, ‘high’ risk of bias or ‘unclear’. Where our judge-
ment is unclear we will attempt to contact the authors
for clarification.
Assessment of adequacy of monitoring and reporting bias
Monitoring and reporting bias will be assessed using a
specifically designed tool. The tool will review:
▸ the adequacy of laboratory monitoring: the tests con-
ducted, the timing of the tests, the validity of the
tests;
▸ the completeness of the reporting of the tests;
▸ the independence of data analysis from the study
sponsor.
Dealing with missing data
The primary analysis will be a complete case analysis. If
data from the trial reports are insufficient, unclear or
missing, we will attempt to contact the authors for add-
itional information.
Assessment of heterogeneity
We will assess for heterogeneity by assessing the forest
plots for overlapping CIs, reporting the I² statistic with a
level of 50% to denote moderate levels of heterogeneity
and applying the χ2 test with a p value of 0.10 to indicate
statistical significance.
Data analysis
The primary analysis will group studies by study design
as follows.
Randomised or quasi-randomised controlled trials:
▸ where G6PD deficient individuals are allocated to
treatment with PQ /8AQ or without PQ /8AQ;
▸ where individuals with G6PD deficiency are allocated
to different doses of PQ /8AQ.
Non-randomised controlled studies:
▸ where individuals with G6PD deficiency are treated
with PQ /8AQ or without PQ /8AQ;
▸ where individuals with G6PD deficiency are treated
with different doses of PQ /8AQ;
▸ where individuals with G6PD deficiency and non-
deficient individuals are treated with the same dose
of PQ /8AQ.
Non-randomised uncontrolled studies:
▸ single-arm studies where individuals with G6PD defi-
ciency are treated with one specific PQ /8AQ dose.
Where studies report a control group, we will compare
dichotomous outcomes using risk ratios and continuous
outcomes using mean differences. All results will be pre-
sented with 95% CIs. In the absence of heterogeneity we
will use a fixed-effect model to combine studies, and
where we detect moderate heterogeneity and it is still
reasonable to combine trials we will use a random-effects
model.
We will assess the quality of evidence using the
GRADE approach.38
Subgroup analysis and investigation of heterogeneity
Where there are sufficient data we will stratify our ana-
lysis by the degree of G6PD deficiency, using standard
classifications based on phenotypes.
Where data allow we will also stratify the analysis by
total dose (low <0.4 mg/kg/day, medium 0.4–<0.6 mg/
kg/day or high ≥0.6 mg/kg/day dose).
We explore for other potential causes of heterogeneity
by additional subgroup analyses by age, gender, weight,
type of malaria, level of parasitaemia and intensity of
malaria transmission.
Sensitivity analysis
When there are sufficient data, we will conduct sensitiv-
ity analyses to investigate the robustness of the estimates
for the primary outcomes by excluding trials at high risk
of bias.
We will also explore the potential effects of participant
withdrawals by conducting a sensitivity analysis, where
excluded trial participants are first added back into the
analysis as having experienced the outcome and second
as not experiencing the outcome.
ETHICS AND DISSEMINATION
This systematic review will be published in a peer-
reviewed journal. It will also be presented at national
and international conferences in the fields of malaria
and at the Cochrane colloquium. Brief reports of the
review findings will be disseminated directly to the
appropriate audiences and the WHO Technical Expert
Group in Malaria Chemotherapy. As no primary data
collection will be undertaken, no additional formal
ethical assessment and informed consent are required.
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